Asarina Pharma AB (STU:APS) Debt-to-Asset : 0.16 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Asarina Pharma AB Debt-to-Asset?

Asarina Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.09 Mil. Asarina Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Asarina Pharma AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €0.54 Mil. Asarina Pharma AB's debt to asset for the quarter that ended in Dec. 2023 was 0.16.

Asarina Pharma AB Debt-to-Asset Historical Data

The historical data trend for Asarina Pharma AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB Debt-to-Asset Chart

Asarina Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.18

0.16

Asarina Pharma AB Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.21	-	-	-	0.16

Competitive Comparison of Asarina Pharma AB's Debt-to-Asset

For the Biotechnology subindustry, Asarina Pharma AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Asarina Pharma AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Asarina Pharma AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Asarina Pharma AB's Debt-to-Asset falls into.

Asarina Pharma AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Asarina Pharma AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.089	+	0)	/	0.543
	=	0.16

Asarina Pharma AB's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.089	+	0)	/	0.543
	=	0.16

Asarina Pharma AB (STU:APS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Asarina Pharma AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Asarina Pharma AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Asarina Pharma AB (STU:APS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (STU:APS) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ASAP:Sweden

Address

Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65

Website

https://www.asarinapharma.com

Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB (STU:APS) Headlines

No Headlines